Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels

Journal of Hepatology

Volumn 46, Issue 3, 2007, Pages 403-410

  Akuta, Norio ^a   Suzuki, Fumitaka ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Suzuki, Yoshiyuki ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Kobayashi, Mariko ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Core region; Double wild type; Early virologic response; HCV; ICG R15; LDL cholesterol; Mutation specific primer; Peginterferon; Ribavirin; Sustained virological response

Indexed keywords

AMINO ACID; ARGININE; GAMMA GLUTAMYLTRANSFERASE; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; JAPANESE; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; LIVER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL CORE PROTEINS;

EID: 33846593397     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.09.019     Document Type: Article

References (42)

1. Fried M.W., Shiffman M.L., Reddy R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
2. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-20.
3. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
4. Akuta N., Suzuki F., Sezaki H., Suzuki Y., Hosaka T., Someya T., et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48 (2005) 372-380
5. Akuta N., Suzuki F., Sezaki H., Suzuki Y., Hosaka T., Someya T., et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load. J Med Virol 78 (2006) 83-90
6. D'Souza R., Sabin C.A., and Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100 (2005) 1509-1515
7. Martinez-Bauer E., Crespo J., Romero-Gomez M., Moreno-Otero R., Sola R., Tesei N., et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 43 (2006) 72-80
8. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 (2003) 75-85
9. Akuta N., Suzuki F., Tsubota A., Suzuki Y., Someya T., Kobayashi M., et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 37 (2002) 831-836
10. Chayama K., Tsubota A., Arase Y., Saitoh S., Koida I., Ikeda K., et al. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 8 (1993) 150-156
11. Desmet V.J., Gerber M., Hoofnagle J.H., Manna M., and Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
12. D'Alessandro A.M., Kalayouglu M., Sollinger H.W., Hoffmann R.M., Reed A., Knechtle S.J., et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 51 (1991) 157-163
13. Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. J Virol Methods (in press).
14. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87 (1990) 9524-9528
15. Kwok S., and Higuchi R. Avoiding false positives with PCR. Nature 339 (1989) 237-238
16. Blindenbacher A., Duong F.H., Hunziker L., Stutvoet S.T., Wang X., Terracciano L., et al. Expression of hepatitis C virus proteins inhibits interferon α signaling in the liver of transgenic mice. Gastroenterology 124 (2003) 1465-1475
17. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., et al. IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17 (2003) 488-490
18. Melén K., Fagerlund R., Nyqvist M., Keskinen P., and Julkunen I. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol 73 (2004) 536-547
19. de Lucas S., Bartolome J., and Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 191 (2005) 93-99
20. Voltides G., Sorensen A.S., Kopp F., Zitzmann K., Cengic N., Brand S., et al. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 30 (2004) 1007-1014
21. Gopal K., Johnson T.C., Gopal S., Walfish A., Bang C.T., Suwandhi P., et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44 (2006) 335-340
22. Agnello V., Abel G., Elfahal M., Knight G.B., and Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96 (1999) 12766-12771
23. Andre P., Komurian-Pradel F., Deforges S., Perret M., Berland J.L., Sodoyer M., et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76 (2002) 6919-6928
24. Ye J., Wang C., Sumpter R., Brown M.S., Goldstein J.L., and Gale M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 100 (2003) 15865-15870
25. Kapadia S.B., and Chisari F.V. Hepatitis C virus replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 102 (2005) 2561-2566
26. Ikeda M., Abe K., Yamada M., Dansako H., Naka K., and Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44 (2006) 117-125
27. Netea M.G., Demacker P.N.M., Kullberg B.J., Boerman O.C., Verschueren I., Stalenhoef A.F.H., et al. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest 97 (1996) 1366-1372
28. Ludewig B., Jaggi M., Dumrese T., Brduscha-Riem K., Odermatt B., Hengartner H., et al. Hypercholesterolemia exacerbates virus-induced immunopathologic liver disease via suppression of antiviral cytotoxic T cell responses. J Immunol 166 (2001) 3369-3376
29. Muldoon M.F., Marsland A., Flory J.D., Rabin B.S., Whiteside T.L., and Manuck S.B. Immune system differences in men with hypo- or hypercholesterolemia. Clin Immunol Immunopathol 84 (1997) 145-149
30. Schaefer E.J., Lamon-Fava S., Johnson S., Ordovas J.M., Schaefer M.M., Castelli W.P., et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb 14 (1994) 1105-1113
31. Mueller T., Gessner R., Sarrazin C., Graf C., Halangk J., Witt H., et al. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology (2003) 1592 (Correspondence)
32. McHutchison J.G., Poynard T., Pianko S., Gordon S.C., Reid A.E., Dienstag J., et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 119 (2000) 1317-1323
33. Kaplan D.E., Sugimoto K., Ikeda F., Stadanlick J., Valiga M., Shetty K., et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 41 (2005) 1365-1375
34. Borenstein A.R., Mortimer J.A., Wu Y., Jureidini-Webb F.M., Fallin M.D., Small B.J., et al. Apolipoprotein E and cognition in community-based samples of African Americans and Caucasians. Ethn Dis 16 (2006) 9-15
35. Nakano I., Fukuda Y., Katano Y., Nakano S., Kumada T., and Hayakawa T. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?. J Hepatol 30 (1999) 1014-1022
36. Jouet P., Roudot-Thoraval F., Dhumeaux D., and Metreau J.M. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106 (1994) 686-690
37. Poynard T., McHutchinson J., Goodman Z., Ling M.H., and Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Group. Hepatology 31 (2000) 211-218
38. Bruno S., Camma C., Di Marco V., Rumi M., Vinci M., Camozzi M., et al. Peginterferon alfa-2b plus ribavirin for nai{dotless}̈ve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 41 (2004) 474-481
39. Stremmel W., Wojdat R., Groteguth R., Zoedler M., Ebener T., Niederau C., et al. Liver function tests in a clinical comparison. Gastroenterology 30 (1992) 784-790
40. Conjeevaram H.S., Fried M.W., Jeffers L.J., Terraults N.A., Wiley-Lucas T.E., Afdhal N., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131 (2006) 147-470
41. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 (2003) 600-609
42. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965